Loading...
•
Dec 31, 2023
Corvus Pharmaceuticals Q4 2023 Earnings Report
Corvus Pharmaceuticals reported financial results for Q4 2023 and provided a business update.
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $6.7 million for the fourth quarter of 2023, compared to a net loss of $9.8 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $27.1 million as of December 31, 2023.
Soquelitinib is advancing towards initial enrollment for a registrational Phase 3 clinical trial for PTCL and a randomized Phase 1 clinical trial for atopic dermatitis.
Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib’s potential to address the need for new treatments for PTCL.
The company anticipates the atopic dermatitis trial will be initiated in the second quarter of 2024 with initial data potentially available by year end.
The company anticipates the PTCL trial will be initiated in the third quarter.
Corvus Pharmaceuticals
Corvus Pharmaceuticals
Forward Guidance
Corvus Pharmaceuticals anticipates initiating a Phase 3 trial for soquelitinib in PTCL and a Phase 1 trial in atopic dermatitis.
Positive Outlook
- Initiation of Phase 3 trial for soquelitinib in PTCL anticipated in Q3.
- Initiation of Phase 1 trial for soquelitinib in atopic dermatitis anticipated in Q2 2024.
- Potential for initial data from the atopic dermatitis trial by year-end.
- Positive updates from Phase 1/1b clinical trial for soquelitinib.
- Alignment on the final study protocol with FDA for the PTCL trial.
Challenges Ahead
- The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of soquelitinib and its other product candidates
- The accuracy of the company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials
- The results of preclinical studies and interim data from clinical trials not being predictive of future results
- The company’s ability to enroll sufficient numbers of patients in its clinical trials
- The unpredictability of the regulatory process